Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (6073)	5/13/1999 8:27:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

continuing to deliver..... "Gross margins on North American sales of VIRACEPT increased for the eighth consecutive quarter to 73% compared to 66% for the same period a year ago."

To: billkirn who wrote (6073)	5/14/1999 2:25:00 PM
From: Ross	Read Replies (1) \| Respond to of 6136

With regards to the value at conversion- I know people here have gone over this, but if you go to the investor relations page at agouron.com, you can call up a chart on which it states that if the Warner price is between $64.52 and $74, you receive $60 of WLA stock. Based on this, I don't see how you get a higher number. The Agouron web page might be a simplification of a more complicated formula given in an official filing, but it seems very clear.